Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells

1 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer. J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660 Search in Google Scholar

2 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68(6) (2018) 394–424; https://doi.org/10.3322/caac.21492 Search in Google Scholar

3 H. Su, H. Jiang, T. Tao, X. Kang, X. Zhang, D. Kang, S. Li, C. Li, H. Wang, Z. Yang and C. Li, Hope and challenge: Precision medicine in bladder cancer, Cancer Med. 8(4) (2019) 1806–1816; https://doi.org/10.1002/cam4.1979 Search in Google Scholar

4 S. K. Bhanvadia, Bladder cancer survivorship, Curr. Urol. Rep. 19(12) (2018) Article ID 111; https://doi.org/10.1007/s11934-018-0860-6 Search in Google Scholar

5 M. Babjuk, M. Burger, O. Capoun, D. Cohen, E. M. Compérat, J. L. Dominguez Escrig, P. Gontero, F. Liedberg, A. Masson-Lecomte, A. H. Mostafid, J. Palou, B. W. G. van Rhijn, M. Rouprêt, S. F. Shariat, T. Seiseu, V. Soukup and R. J. Sylvester, European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ), Eur. Urol. 81(1) (2022) 75–94; https://doi.org/10.1016/j.eururo.2021.08.010 Search in Google Scholar

6 C. Seidl, Targets for therapy of bladder cancer, Semin. Nucl. Med. 50(2) (2020) 162–170; https://doi.org/10.1053/j.semnuclmed.2020.02.006 Search in Google Scholar

7 J. A. Witjes, H. M. Bruins, R. Cathomas, E. M. Compérat, N. C. Cowan, G. Gakis, V. Hernández, E. Linares Espinós, A. Lorch, Y. Neuzillet, M. Rouanne, G. N. Thalmann, E. Veskimäe, M. J. Ribal, A. G. van der Heijden, European Association of Urology Guidelines on Muscle-invasive and Meta-static Bladder Cancer: Summary of the 2020 Guidelines, Eur. Urol. 79(1) (2021); https://doi.org/10.1016/j.eururo.2020.03.055 Search in Google Scholar

8 J. Bellmunt and D. P. Petrylak, New therapeutic challenges in advanced bladder cancer, Semin Oncol. 39(5) (2012) 598–607; https://doi.org/10.1053/j.seminoncol.2012.08.007 Search in Google Scholar

9 M. D. Galsky, S. K. Pal, S. Chowdhury, L. C. Harshman, S. J. Crabb, Y.-N. Wong, E. Y. Yu, T. Powles, E. L. Moshier, S- Ladoire, S. A. Hussain, N. Agarwal, U. N. Vaishampayan, F. Recine, D. Berthold, A. Nechi, C. Theodore, M. I. Milowsky, J. Bellmunt and J. Rosenberg, Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer, Cancer 121(15) (2015) 2586–2593; https://doi.org/10.1002/cncr.29387 Search in Google Scholar

10 H. B. Grossman, R. B. Natale, C. M. Tangen, V. O. Speights, N. J. Vogelzang, D. L. Trump, R. W. deVere White, M. F. Sarosdy, D. P. Wood. Jr, D. Raghavan and E. D. Crawford, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N. Engl. J. Med. 349(9) (2003) 859–866; https://doi.org/10.1056/NEJMoa022148 Search in Google Scholar

11 C. N. Sternberg, I. Skoneczna, J. M. Kerst, P. Albers, S. D. Fossa, M. Agerbaek, H. Dumez, M. de Santis, C. Théodore, M. G. Leachy, J. D. Chester, A. Verbaeys, G. Daugaard, L. Wood, V. A. Vitjes, R. de Wit, L. Geoffrois, L. Sengelov, G. Thalmann, D. Charpentier, F. Rolland, L. Mignot, S. Sundar, P. Symonds, J. Graham, F. Joly, S. Marreaud, L. Collette and R. Sylvester, Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial, Lancet Oncol. 16(1) (2015) 76–86; https://doi.org/10.1016/S1470-2045(14)71160-X Search in Google Scholar

12 A. V. Balar, M. D. Galsky, J. E. Rosenberg, T. Powles, D. P. Petrylak, J. Bellmunt, Y. Loriot, A. Necchi, J. Hoffman-Censits, J. L. Perez-Gracia, N. A. Dawson, M. S. van der Heijden, R. Dreicer, S. Srinivas, M. M. Retz, R. Joseph, A. Drakaki, U. N. Vaishampayan, S. S. Gridhar, D. I. Quinn, I. Duron, D. Shaffer, B. J. Eigl, P. D. Grivas, E. Y. Yu, S. Li, E. E. Kadel III, Z. Boyd, R. Burgon, P. S. Hegde, S. Mariathasan, A. K. Thåström, O. O. Abidoye, G. D. Fine and D. F. Bajorin, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet 389(10064) (2017) 67–76; https://doi.org/10.1016/S0140-6736(16)32455-2 Search in Google Scholar

13 M. De Santis, J. Bellmunt, G. Mead, J. M. Kerst, M. Leahy, P. Maroto, T. Gil, S. Marreaud, S. Collette, J. Lorent and R. Sylvester, Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J. Clin. Oncol. 30(2) (2012) 191–199; https://doi.org/10.1200/jco.2011.37.3571 Search in Google Scholar

14 Y. Xiang, Z. Guo, P. Zhu, J. Chen and Y. Huang, Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science, Cancer Med. 8(5) (2019) 1958–1975; https://doi.org/10.1002/cam4.2108 Search in Google Scholar

15 Y. Xia, S. Chen, J. Cui, Y. Wang, X. Liu, Y. Shen, L. Gong, X. Jiang, W. Wang, Y. Zhu, S. Sun, J. Li, Y. Zou and B. Shi, Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p, Biochem. Pharmacol. 188 (2021) Article ID 114575; https://doi.org/10.1016/j.bcp.2021.114575 Search in Google Scholar

16 W. Niu, L. Xu, J. Li, Y. Zhai, Z. Sun, W. Shi, Y. Jiang, C. Ma, H. Lin, Y. Guo and Z. Liu, Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs, Oncol. Lett. 20(3) (2020) 2928–2936; https://doi.org/10.3892/ol.2020.11839 Search in Google Scholar

17 X.-Z. Liao, L.-T. Tao, J.-H. Liu, Y.-Y. Gu, J. Xie, Y. Chen, M.-G. Lin, T.-L. Liu, D. M. Wang, H. Y. Guo and S. L. Mo, Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway, Cancer Cell Int. 17 (2017) Article ID 124 (14 pages); https://doi.org/10.1186/s12935-017-0495-6 Search in Google Scholar

18 I. Muhammad, M. R. Jacob, M. A. Ibrahim, V. Raman, M. Kumarihamy, M. Wang, T. Al-Adhami, C. Hind, M. Clifford, B. Martin, J. Zhao, J. M. Sutton and K. M. Rahman, Antimicrobial constituents from Machaerium Pers.: Inhibitory activities and synergism of machaeriols and machaeridiols against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and permeabilized Gram-negative pathogens, Molecules 25(24) (2020); https://doi.org/10.3390/molecules25246000 Search in Google Scholar

19 H. Chen, X. Zhao, T. Lv, X. Qiu, L. Luo, M. Zhang, H. Yang, X. Chang, P. Li, C. L. Wu, D. Xie, Y. Quian and C. Yang, Compounds from the root of Pueraria peduncularis (Grah. ex Benth.) Benth. and their antimicrobial effects, Pest. Manag. Sci. 75(10) (2019) 2765–2769; https://doi.org/10.1002/ps.5387 Search in Google Scholar

20 A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and S. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice, Mol. Cell. Endocrin. 325(1-2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016 Search in Google Scholar

21 G. Gatouillat, A. A. Magid, E. Bertin, H. El Btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells, Inter. J. Phytother. Phytopharmacol. 22(13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005 Search in Google Scholar

22 R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROSJNK-CHOP pathway, Cell Death Disease 5(10) (2014) Article ID e1465 (10 pages); https://doi.org/10.1038/cddis.2014.429 Search in Google Scholar

23 H. Su, T. Tao, Z. Yang, X. Kang, X. Zhang, D. Kang, S. Wu and C. Li, Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression, Mol. Cancer 18(1) (2019) Article ID 27 (15 pages); https://doi.org/10.1186/s12943-019-0951-0 Search in Google Scholar

24 Z. Yang, C. Li, Z. Fan, H. Liu, X. Zhang, Z. Cai, L. Xu, J. Luo, Y. Huang, L. He, C. Liu and S. Wu, Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells, Eur. Urol. 71(1) (2017) 8–12; https://doi.org/10.1016/j.eururo.2016.06.025 Search in Google Scholar

25 E. C. Jensen, Quantitative analysis of histological staining and fluorescence using ImageJ, Anat. Rec. (Hoboken). 296(3) (2013) 378–381; https://doi.org/10.1002/ar.22641 Search in Google Scholar

26 S. Antoni, J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal and F. Bray, Bladder cancer incidence and mortality: A global overview and recent trends, Eur. Urol. 71(1) (2017) 96–108; https://doi.org/10.1016/j.eururo.2016.06.010 Search in Google Scholar

27 S. Cambier, R. J. Sylvester, L. Collette, P. Gontero, M. A. Brausi, G. van Andel, W. J. Kirkels, F. C. Silva, W. Oosterlinck, S. Prescott, Z. Kirkali, P. H. Powell, T. M. Reijke, L. Turkeri, S. Collette and J. Oddens, EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin, Eur. Urol. 69(1) (2016) 60–69; https://doi.org/10.1016/j.eururo.2015.06.045 Search in Google Scholar

28 S. Wang, S. Long and W. Wu, Application of traditional chinese medicines as personalized therapy in human cancers, Am. J. Chin. Med. 46(5) (2018) 953–970; https://doi.org/10.1142/s0192415x18500507 Search in Google Scholar

29 D. Y. Zhang, Y. B. Cheng, Q. H. Guo, X. L. Shan, F. F. Wei, F. Lu, C. S. Sheng, Q. F. Huang, C. H. Yang, Y. Li and J. G. Wang, Treatment of masked hypertension with a chinese herbal formula: a randomized, placebo-controlled trial, Circulation 142(19) (2020) 1821–1830; https://doi.org/10.1161/circulationaha.120.046685 Search in Google Scholar

30 J. Tian, D. Jin, Q. Bao, Q. Ding, H. Zhang, Z. Gao, J. Song, F. Lian and X. Tong, Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: A systematic review and meta-analysis, Diab. Obes. Metabol. 21(8) (2019) 1801–1816; https://doi.org/10.1111/dom.13760 Search in Google Scholar

31 F. Huang, X. Zheng, X. Ma, R. Jiang, W. Zhou, S. Zhou, Y. Zhang, S. Lei, S. Wang, J. Kuang, X. Han, M. Wei, Y. You, M. Li, Y. Li, D. Liang. J. Liu, T. Chen, C. Yan, R. Wei C. Rajani, C. Shen, G. Xies, Z. Bian, H. Li, A. Zhao and W. Jia, Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism, Nature Comm. 10(1) (2019) Article ID 4971 (17 pages); https://doi.org/10.1038/s41467-019-12896-x Search in Google Scholar

32 K. Jiang, H. Chen, K. Tang, W. Guan, H. Zhou, X. Guo, Z. Chen, Z. Ye and H. Xu, Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway, Oncol. Lett. 15(1) (2018) 167–174; https://doi.org/10.3892/o1.2017.7298 Search in Google Scholar

33 F. Wang, J. Tang, P. Li, S. Si, H. Yu, X. Yang, J. Tao, Q. Lv, M. Gu, H. Yang and Z. Wang, Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis, Cell Physiol. Biochem. 45(1) (2018) 54–66; https://doi.org/10.1159/000486222 Search in Google Scholar

34 B. O’Leary, R. S. Finn and N. C. Turner, Treating cancer with selective CDK4/6 inhibitors, Nat. Rev. Clin. Oncol. 13(7) (2016) 417–430; https://doi.org/10.1038/nrclinonc.2016.26 Search in Google Scholar

35 F. Zhao, O. Vakhrusheva, S. D. Markowitsch, K. S. Slade, I. Tsaur, J. Cinatl, Jr., M. Michaelis, T. Efferth, A. Haferkamf and E. Juengel, Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction, Cells. 9(12) (2020) Article ID 2643 (19 pages); https://doi.org/10.3390/cells9122643 Search in Google Scholar

36 R. M. Mohammad, I. Muqbil, L. Lowe, C. Yedjou, H. Y. Hsu, L. T. Lin, M. D. Siegelin, C. Fimognari, N. B. Kumar, Q. P. Dou, H. Yang, A. K. Samadi, G. L. Russo, C. Spagnuolo, S. K. Ray, M. Chakrabarti, J. D. Morre, H. M. Coley, H. Fuji and A. S. Azmi, Broad targeting of resistance to apoptosis in cancer, Sem. Cancer Biol. 35 Suppl (0) (2015) S78–103; https://doi.org/10.1016/j.semcancer.2015.03.001 Search in Google Scholar

37 R. S. Wong, Apoptosis in cancer: from pathogenesis to treatment, J. Exp. Clin. Cancer Res. 30(1) (2011) Article ID 87 (14 pages); https://doi.org/10.1186/1756-9966-30-87 Search in Google Scholar

38 B. A. Carneiro and W. S. El-Deiry, Targeting apoptosis in cancer therapy, Nat. Rev. Clin. Oncol. 17(7) (2020) 395–417; https://doi.org/10.1038/s41571-020-0341-y Search in Google Scholar